Omalizumab Improves Sleep in Patients With Chronic Idiopathic, Spontaneous Urticaria

25 novembre 2014 - 09:17Rassegna stampa

Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who were treated with omalizumab reported a reduction in sleep problems compared with those who received placebo, according to a study presented here at the Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI).

"Improvement in sleep impairment was achieved after 4 weeks" wrote Evgeniya Antonova, PhD, Genentech, San Francisco, California, and colleagues in their poster presentation.

CIU/CSU greatly affects patient health-related quality of life, and its symptoms often result in poor sleep quality and inadequate duration.

For the current analysis, researchers scrutinised patient-reported data on sleep from the randomised, double-blind, placebo-controlled GLACIAL trial, which included patients aged 12 to 75 years with CIU/CSU who remained symptomatic on H1-antihistamine treatment plus H2-antihistamines and/or leukotriene receptor antagonists.

Patients were randomised to receive either omalizumab 300 mg (n = 252) or placebo (n = 83) every 4 weeks for a total of 6 doses, and they were followed for an additional 16 weeks of observation after the dosing was completed.

The patients' sleep quality was evaluated using the Urticaria Patient Daily Diary (UPDD; sleep interference question), Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL; sleep problems dimension), and the Medical Outcomes Study Sleep Scale (MOS-SS; sleep problem index II [SPIII]).

By week 12, patients in both the treatment and placebo groups experienced improvement in sleep, compared with baseline. However, the omalizumab group showed a larger reduction in patient-reported sleep problems than the placebo group (mean, % reduction) for MOS-SS SPI-II scores (-19.0 vs -13.4); for UPDD sleep interference item score (-9.2 vs -5.0); and for the CU-Q2oL Sleep Problems score (- 29.4 vs -18.3).

Funding for this study was provided by Genentech, Inc. and Novartis Pharma AG.

Inserito da segreteria SIDeMaST

La rassegna stampa contiene articoli di interesse dermatologico tratti da testate nazionali e non intende fornire una revisione critica né essere una fonte di notizie scientificamente validate. Si accettano (e sono bene graditi) commenti da parte dei soci esperti nel settore.

Lascia un commento sul sito e rispondi all'autore

I commenti sono soggetti a moderazione: non saranno pubblicati immediatamente ma dovranno essere approvati dalla segreteria.

Eventi SIDeMaST

Stato iscrizione